Sharon Worcester
Reporter at MDedge Hematology and Oncology
Medical journalist. Writer. Believer in love and hope and science. Ally. Views my own. She/Her. Latest book: The Doctor As The Patient
Articles
-
2 weeks ago |
medscape.com | Sharon Worcester
The American Society of Clinical Oncology (ASCO) and Google Cloud have recently launched an artificial intelligence (AI)–powered search tool to provide accurate and fast access to ASCO’s full library of evidence-based clinical guidelines, the society announced this week.
-
2 weeks ago |
mdedge.com | Sharon Worcester
Rates of certain cancers in the United States — including breast, colorectal, and thyroid cancers — increased between 2010 and 2019 among patients aged less than 50 years, while overall cancer incidence and mortality rates did not increase, a new study found. Among the more than two million cases of early-onset cancer diagnosed during this period, 63.2% were in women, researchers reported recently in Cancer Discovery.
-
2 weeks ago |
medscape.com | Sharon Worcester
Rates of certain cancers in the United States — including breast, colorectal, and thyroid cancers — increased between 2010 and 2019 among patients aged less than 50 years, while overall cancer incidence and mortality rates did not increase, a new study found. Among the more than two million cases of early-onset cancer diagnosed during this period, 63.2% were in women, researchers reported recently in Cancer Discovery.
-
1 month ago |
medscape.com | Sharon Worcester
The US Food and Drug Administration (FDA) has granted accelerated approval of combination avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for the treatment of certain patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). Specifically, approval is for adults who received at least one prior systemic therapy, including a platinum-based regimen, according to the FDA approval notice.
-
1 month ago |
medscape.com | Sharon Worcester
The US Food and Drug Administration (FDA) has approved penpulimab-kcqx (Akeso Biopharma) in combination with cisplatin or carboplatin and gemcitabine as first-line treatment for adults with certain types of nasopharyngeal carcinoma (NPC), and as a single agent for certain patients with NPC disease progression on or after other treatments.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 213
- Tweets
- 216
- DMs Open
- No
I'm heading to bluer skies...if you're there, please give me a follow at sw-medreporter!
This. It matters!
I'm going to choose my words here with care: When you vote, remember the anger you felt when you first understood SCOTUS was going to reverse Roe v. Wade. Whatever it takes. Vote. Make sure the people around you vote. It matters.
So, I'm doing 'a thing.' Pretty excited about this book project and would love #MedTwitter input on the doctor-as-patient experience. In a nutshell, what's the greatest and/or most surprising lesson learned from "the other side of the consultation desk?" https://t.co/r2wSlEsO0Q
